Developers of the CoviVac vaccine published results of the first two phases of studies on safety and immunogenicity conducted with the participation of volunteers from 18 to 60 years old.
experts, interviewees The BBC Russian Service (the media recognized it as a foreign agent) notes the extremely low effectiveness of the vaccine.
PhD Tatyana Dudnakova from the School of Biological Sciences at the University of Edinburgh recalled that the real effectiveness of KoviVac can only be assessed by the results of the third phase of research. But we already see [по группам „народных отчетов“ в „Фейсбуке“ и „Телеграме“]that it is very low, there is almost no protection even from a severe course, ”says the expert.
The researcher pointed to the poor ability of the vaccine to neutralize the virus before it enters the cell. The titers of antibodies produced by the body after vaccination are low, Dudnakova added. The average titer, according to published data, is 1:10. At the same time, to maintain a high degree of protection against delta strains, titers of 1:80 – 1:120 are needed. 13% of study participants did not develop antibodies at all.
Meanwhile, the probability of penetration of “omicron” into the cell is even greater than that of “delta”. Presumably, the titers to neutralize the new strain should be higher.
